Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the 33 rd Annual Roth Conference , which will be held virtually on March 15-17, 2021 .
|
NEW YORK, Feb. 17, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the 33rd Annual Roth Conference, which will be held virtually on March 15-17, 2021.
Raj Mehra, Ph.D., Chairman and CEO, will host 1x1 meetings via conference calls on March 16th and 17th. About Seelos Therapeutics Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare diseases. The Company's robust portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder (MDD) or Post-Traumatic Stress Disorder (PTSD), amyotrophic lateral sclerosis (ALS), Sanfilippo syndrome, Parkinson's disease, other psychiatric and movement disorders plus orphan diseases. For more information, please visit our website: http://seelostherapeutics.com, the content of which is not incorporated herein by reference. Contact Information: Anthony Marciano
SOURCE Seelos Therapeutics, Inc. |
||
Company Codes: NASDAQ-NMS:SEEL |
View original content to download multimedia:
